The WHO has granted India’s Covaxin COVID-19 vaccine emergency authorization.

Covid19 vaccine

According to the WHO, the vaccine has a 78 percent efficiency after two doses and is “very suited for poor and middle-income nations.”
The World Health Organization (WHO) has listed India’s Covaxin vaccine against COVID-19 as an emergency use item.
The vaccine “is very suitable for low- and middle-income countries due to simple storage requirements,” the UN’s health agency said in a statement on Wednesday, after its Strategic Advisory Group of Experts judged it to have 78 percent efficacy after two doses spread over four weeks last month.
“This emergency use listing increases the availability of vaccines, which are the most powerful medical instruments we have to combat the epidemic,” said Mariangela Simao, WHO’s assistant director-general for access to medicines and health products.
“However, we must maintain pressure to satisfy the demands of all populations, giving priority to at-risk groups who are still waiting for their first dose before we can declare triumph,” she added.
Locally developed
Covaxin was created in India by the Indian business Bharat Biotech in collaboration with the Indian Council of Medical Scientific, the government’s highest research authority.
Bharat Biotech applauded the WHO clearance, saying it “validates Covaxin’s international safety and quality standards.”
While a WHO-convened expert council concluded inadequate data on the vaccine’s safety and efficacy in pregnant women, studies are being planned to address those concerns.
Covaxin was approved by India’s drug authority in January, months before substantial human testing was completed, raising concerns among health experts that the shot was approved too soon.
Increasing Production
Despite India’s continuous support for its domestic vaccine, Bharat Biotech has struggled to scale up production.
In July, India’s health ministry stated that the business was producing 25 million doses of the vaccine annually, with monthly output expected to climb to 58 million doses.
The company claims an annual capacity of 1 billion doses by the end of 2021, or more than 80 million shots each month, but has not responded to concerns regarding its presentability.
Bharat Biotech stated that its COVID-19 vaccine had been approved in several other countries, including Brazil, the Philippines, Iran, and Mexico.


Leave a Reply

Your email address will not be published. Required fields are marked *